Title:
EBV COMPOSITE ANTIGEN, DENDRITIC CELL VACCINE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/005486
Kind Code:
A1
Abstract:
Provided are an EBV composite antigen, a dendritic cell vaccine and the use thereof for preparing an EBV-related infectious disease drug, which belong to the technical field of biomedicine. A dendritic cell of a patient is stimulated in vitro, loaded with a variety of EBV infected cell lysates with super-strong immunogenicity against EBV-associated infectious diseases, and induced to be mature under the conditions of a variety of cytokines and a specific agonist, so as to form a complete dendritic cell vaccine with a corresponding antigen; and the complete dendritic cell vaccine is transported back to a human body to activate the immune system, so as to generate a cytotoxic T cell and kill EBV infected cells. The dendritic cell vaccine exerts an immunological effect and improves the life quality of a patient. The preparation period thereof is about 1 week, and therefore the dendritic cell vaccine is short in time, low in cost, safe, and almost completely free of side effects.
Inventors:
LIU HELEN (CN)
LIU HELEN (CN)
YIN ZE (CN)
LIU HELEN (CN)
YIN ZE (CN)
Application Number:
PCT/CN2022/099296
Publication Date:
February 02, 2023
Filing Date:
June 17, 2022
Export Citation:
Assignee:
SHANGHAI HENGSAI BIOLOGICAL TECH CO LTD (CN)
LIU HELEN (CN)
LIU HELEN (CN)
International Classes:
A61K39/245; A61K39/39; A61K45/06; A61P31/22; A61P35/00; A61P35/04
Foreign References:
| CN113521270A | 2021-10-22 | |||
| CN114246942A | 2022-03-29 | |||
| US20110306948A1 | 2011-12-15 |
Other References:
HERR, W. ET AL.: "Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses", BLOOD, vol. 96, no. 5, 1 September 2000 (2000-09-01), XP002203121, ISSN: 0006-4971
SUGANO, M. ET AL.: "Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell(BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response", JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH., ROME., IT, vol. 20, no. 2, 30 June 2001 (2001-06-30), IT , pages 175 - 182, XP009543019, ISSN: 0392-9078
SUGANO, M. ET AL.: "Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell(BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response", JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH., ROME., IT, vol. 20, no. 2, 30 June 2001 (2001-06-30), IT , pages 175 - 182, XP009543019, ISSN: 0392-9078
Attorney, Agent or Firm:
SHANGHAI ZHESHENG INTELLECTUAL PROPERTY AGENCY (GENERAL PARTNERSHIP) (CN)
Download PDF: